The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
ATLANTA, Georgia — Patients with chronic obstructive pulmonary disease (COPD) experience few adverse events and discontinuations when treated with an ipratropium plus albuterol inhalation spray (CVT-R ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
October 7, 2011 — The US Food and Drug Administration (FDA) has granted approval for an ipratropium bromide and albuterol sulfate inhalation spray (Combivent Respimat Inhalation Spray, Boehringer ...
RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...
The FDA has advised consumers not to use albuterol sulfate inhalation solution, 0.083%, and ipratropium bromide inhalation solutions, 0.02%, unit-dose vials, purchased after September 8, 2009 and ...
Inhalers are the mainstay of treatment for asthma and chronic obstructive pulmonary disease (COPD). These products face limited generic competition in the US and remain expensive. To better understand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results